Comparing the current results to its competitors, Grace Therapeutics Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 14.13 %, recorded in the same quarter.
Grace Therapeutics Inc, slower than the average decrease reported by the company's competitors of -17.59 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -17.59 %
Grace Therapeutics Inc's Comment on Competition and Industry Peers
The company anticipates its patents will be listed in the US FDA Orange Book, which requires potential competitors to certify when submitting applications referencing its drug products. It protects its proprietary technology through patents, trade secrets, manufacturing expertise, technological innovation, and in-licensing opportunities to sustain its competitive position.
Amarin Corp Plcuk's business model revolves around the development, commercialization, and marketing of innovative pharmaceutical products, particularly focused on cardiovascular health.
Vertex Pharmaceuticals Incs business model centers on the research and development of innovative therapies, primarily targeting cystic fibrosis and other serious diseases. They emphasize collaboration with organizations, strategic partnerships, and robust investment in R&D to deliver transformative treatments to patients and enhance their quality of life.
Verve Therapeutics Inc is a biotechnology company specialized in developing transformative medicines that could permanently prevent cardiovascular diseases through gene editing technology. Their business model revolves around leveraging cutting-edge gene editing techniques to develop novel therapeutics targeting specific genes associated with heart diseases. By utilizing this approach, Verve aims to provide long-term solutions for individuals at risk of cardiovascular ailments, addressing a significant unmet need in the healthcare industry.
Unity Biotechnology Inc. is a biotechnology company that focuses on developing therapies to treat age-related diseases. Their business model revolves around identifying and targeting specific senescent cells to address age-related conditions like osteoarthritis, kidney disease, and ophthalmic diseases. By leveraging their expertise in cellular senescence, Unity Biotechnology aims to develop innovative treatments that have the potential to extend healthy human lifespan.
Sarepta Therapeutics Inc's business model centers around the research, development, and commercialization of innovative genetic medicines for rare diseases, with a particular focus on Duchenne muscular dystrophy (DMD).
Sources:
Grace Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Grace Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
